Isec Healthcare Ltd · SGX:40T
Isec Healthcare — Shareholder Meeting (April 2024)
24 slides from Isec Healthcare's shareholder meeting presentation, Apr 19, 2024
Slide 1: ISEC Healthcare Ltd. 10th Annual General Meeting
SEEING OPPORTUNITIES WITHIN & BEYOND ISEC Healthcare Ltd. (“ISEC Healthcare” or the “Company”) 10th Annual General Meeting Page 0 19th April 2024
Slide 2: Sponsor Statement
This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”) in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual
Slide 3: Disclaimer
Disclaimer This presentation contains certain financial information and results of operation, and may also contain certain projections, plans, strategies and objectives of the Company which are not statements of historical fact but may constitute “forward-looking statements” that reflect the Company
Slide 4: Table of Content
Table of Content Business Overview Financial Highlights Corporate Developments Outlook Page 3
Slide 5: Business Overview
Business Overview Page 4
Slide 6: Introduction: Our Presence
Introduction Our Presence Ipoh 怡保 Myanmar 缅甸 Malacca 马六甲 Kuala Lumpur 吉隆坡 Kampar 金宝 Penang Kuching 槟城 Johor 柔佛 古晋 Singapore Sibu 诗巫 Page 5 新加坡
Slide 7: Business Overview: Our Presence
Business Overview Our Presence Penang Number of Eye Care Centres (as at 19th April 2024): Ipoh and Kampar Malaysia – 8 Singapore – 1 (N1) Kuala Lumpur Myanmar – 1 Melaka N1 – Asia Pacific Eye Centre in Gleneagles Hospital. Kuching Sibu Johor Page 6
Slide 8: Our Competitive Strengths
Business Overview Our Competitive Strengths 1 Highly qualified and experienced specialist doctors 6 Business model aligns the 2 interests of our High quality and specialist doctors with comprehensive range of our Group and eye care services Shareholders 5 Ability to replicate our 3 Well positioned t
Slide 9: Financial Highlights
Financial Highlights Page 8
Slide 10: Revenue – 5 Years (2019 – 2023)
Financial Highlights Revenue – 5 Years (2019 – 2023) S$’Million S$7.0 mil (11%) S$22.5 mil (56%) -S$6.6 mil (-15%) S$4.2 mil (11%) The Group’s revenue increased by 11%, from S$63.0 million in FY2022 to S$70.0 million in FY2023. Generally, the Group showed an upward trend on revenue growth between FY
Slide 11: Revenue Breakdown – By Business Segment
Financial Highlights Revenue Breakdown – By Business Segment Revenue (S$’Million) and Contribution Percentage by Business Segment S$’Million Specialised Health Services: Revenue increased by S$7.5 million, or 13% compared to that in FY2022 largely due to a significant increase in patient visits and
Slide 12: Revenue Breakdown – By Geographical Segment
Financial Highlights Revenue Breakdown – By Geographical Segment Revenue (S$’Million) and Contribution Percentage by Geographical Segment S$’Million Malaysia: Revenue increased by S$6.3 million, or 13% compared to that in FY2022. Excluding contribution from IE Centre and Kampar Eye, which was acquir
Slide 13: Profit attributable to owners of Company – 5 Years
Financial Highlights Profit attributable to owners of Company – 5 Years (2019 – 2023) S$0.5 mil (4%) S$’Million The improved business activities in FY2023 translated to increased profits by S$0.5 million, or 4%, from S$12.5 million in FY2022 to S$13.0 million in FY2023. In FY2020, the Group recognis
Slide 14: Earnings Per Share – 5 Years (2019 – 2023)
Financial Highlights Earnings Per Share – 5 Years (2019 – 2023) Singapore Cents 0.04 cents (2%) Earnings per share increased from 2.22 Singapore cents in FY2022 to 2.26 Singapore cents in FY2023. Page 13
Slide 15: Net Asset Value attributable to owners – 5 Years
Financial Highlights Net Asset Value attributable to owners of Company – 5 Years (2019 – 2023) Net Asset Value attributable to owners of Company Net Asset Value Per Share (S$) (S$’Million) S$’Million S$0.8 mil (1%) S$0.00 (0%) S$ Page 14
Slide 16: Dividends
Financial Highlights Dividends S$’Million N1 Dividend Paid/Proposed (S$’Million) Q2 2023 (Interim Dividend) 4.4 Q4 2023 (Final Dividend) 4.9 Total 9.3 (N1) N1 – Includes final dividend of 0.85 Singapore Cents proposed but not yet approved by the shareholders; to be tabled for approval in the AGM on
Slide 17: Corporate Developments
Corporate Developments Page 16
Slide 18: 2023 – Significant Milestones
Corporate Developments 2023 – Significant Milestones Continue to next slide February 2023 March 2023 ISEC Myanmar expanded its business presence ISEC Kuching has obtained the operating license through its new additional ophthalmology clinic from the Ministry of Health Malaysia and at ARYU Internatio
Slide 19: 2023 – Significant Milestones
Corporate Developments 2023 – Significant Milestones (for illustration only) December 2023 ISEC KL had on 29 December 2023 entered into a Sale and Purchase Agreement to acquire certain strata-title units (the “Parcels”) in a new building to be constructed by Vendor for use and occupation in connecti
Slide 20: Corporate Developments 2024: Specialist Centres Set-Up in Progress
Corporate Developments 2024 Specialist Centres Set-Up in Progress Perak • The three eye centres from the Ipoh Eye Transaction (ME Centre, TE Centre, Taiping Eye) are in the process of obtaining licences. The new centres are expected to commence operations in 2Q 2024. Melaka • We are in the process o
Slide 21: Outlook
Outlook Page 20
Slide 22: Outlook: Well-Positioned to Capture Growing Demand
Outlook • We remain positive about the outlook for our Group as we are well-positioned to capture the growing demand for private eye care services. • As the region ages and current lifestyle patterns continue to be highly influenced by digitalisation, we believe that there will be greater awareness
Slide 23: Political Situation in Myanmar
Outlook Political Situation in Myanmar • As the protests are still ongoing and the situation is still evolving, the Group remains cautiously optimistic and is closely monitoring our clinic operations in Myanmar. • Notwithstanding the political issues in Myanmar, we are very much encouraged by the pe
Slide 24: Thank You
Thank You Page 23